Patient Care and Short-Term Results After Stopping Incretin Agonist Treatment

Obesity medications can produce meaningful weight loss of approximately 5-24% but often lead to treatment discontinuation.

• Up to half of patients may discontinue obesity medications within 1-2 years due to side effects, cost, or limited access.
• Discontinuation of these medications is associated with weight regain and loss of health benefits.
• Two real-world cases illustrate patients experiencing reduced effectiveness upon reintroduction of obesity therapy.
• Effective interim strategies are necessary to maintain weight management progress and minimize long-term health risks.

Simplified